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younger than 65 yearsThierry-Pierre Carrel, MD, and Lars Englberger, MDSee related article by Kaneko et al in the January 2014
issue (J Thorac Cardiovasc Surg. 2014;147:117-26).The group of Cohn and colleagues from Boston1 analyzed
the outcome of patients who received either mechanical
or biologic mitral valve replacement (MVR) by means
of a propensity score analysis. The topic is timely for
publication, because there has actually been a shift to the
use of bioprosthetic valves in younger patients as a result
of potentially feasible later ‘‘valve-in-valve’’ procedures.
Unfortunately, although technically feasible, a valve-in-
valve procedure remains questionable, especially with
regard to optimal hemodynamics. Although the decision
currently is not based on available scientific evidence,
general practitioners and cardiologists are increasingly
recommending biologic prostheses to patients younger
than 60 years.
The same group recently summarized some of the myths
surrounding heart valve prostheses in an article on contro-
versies in cardiovascular medicine.2 The main topics dis-
cussed were the survival of such patients, the need or not
for lifelong anticoagulation, the risk of reoperative surgery,
and the quality of hemodynamics.
If repair of a mitral valve is not possible, the question per-
sists whether a biologic or a mechanical prosthesis should
be preferred for MVR. Recent changes in guideline recom-
mendations (eg, age<65 years no longer being a clear cut-
off for implantation of a mechanical prosthesis) and the
promise of percutaneous valve-in-valve rescue after bio-
prosthetic mitral valve placement have complicated
decision making in MVR.3
The most important reasons to implant a bioprosthesis in
adults younger than 65 years is to decrease the risk of
anticoagulant-related hemorrhagic events and to spare
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The Journal of Thoracic and Cause. Two presumptions, however, are inherent in this argu-
ment: (1) survival of patients after MVR is similar between
mechanical valves and bioprostheses, and (2) current
bioprostheses have longer durability than previous valve
designs, especially in the mitral position.4
The article of Cohn’s group focuses on the long-term
outcome after mechanical versus bioprosthetic MVR in pa-
tients younger than 65 years. Although derived from a retro-
spective analysis, this report contains important
information, because no randomized trials comparing latest
generation bioprosthetic versus mechanical valves in MVR
have yet been performed. The main finding is very clear:
MVR with bioprosthetic valves in patients younger than
65 years was associated with higher rates of reoperation
and decreased survival than was MVR with mechanical
valves. This was true for the total consecutive cohort of pa-
tients as well as for the score-matching subgroup analysis.
Interestingly, these results confirm other reports of aortic
valve replacement in patient cohorts of younger age, in
which survival benefits could be demonstrated after use of
a mechanical prosthesis.5,6
One minor criticism of the article is that the propensity
analysis included patients with a mean age of 53 years.
This is usually not the category of patients in whom there
is discussion concerning the choice of a biologic mitral
valve prosthesis. Patients with a mean age of around 60 to
65 years would have had a better impact for the daily
discussion.
Which factors may explain the finding of better patient
survival with mechanical valve use for MVR? In fact,
several possible explanations other than the mere difference
in valve selection are obvious.
The observational retrospective character of this study
does not exclude the possibility that patient characteristics
(not included in the matching process) could have impor-
tantly confounded the results. Even the matching process
does not compensate for the bias in patient selection with
regard to similar comorbidities (eg, peripheral artery dis-
ease or concomitant pulmonary disease are not reported)
and a similar extent of aortic valve disease. Bioprosthetic
valves could have been preferably implanted in patients
who generally appeared to be more ill and therefore to
have a less favorable presumed life expectancy. We believe
that bioprosthetic valve use for MVR in younger patients
was not performed solely for quality-of-life considerations
(because of the possible benefit of avoiding warfarin) but
also in response to favorable (or less favorable) clinical
characteristics obvious on clinical evaluation but notrdiovascular Surgery c Volume 147, Number 3 853
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the patient group. This consideration may be supported by
the high rate of warfarin therapy for new-onset atrial fibril-
lation in the bioprosthetic valve group, which could be a
sign of advanced cardiac disease.
In addition, differences in survival observed after me-
chanical versus biologic prosthetic valve replacement may
have been influenced by the intrinsic performance of the
prosthesis and the benefits of long-term anticoagulation.
After the implantation of a biologic valve, there is not
only the risk of reoperation for degeneration of this valve
but also the adverse cumulative hemodynamic effect of
living with a degenerating bioprosthesis in place. This
may add a plausible explanation for the improved survival
of patients with mechanical valves.4 Primary tissue failure
of a bioprosthesis may occur earlier in younger patients
and progress more rapidly, and this means that such patients
would be exposed during months or years to a significant
malfunction of the bioprosthesis by regurgitation, stenosis,
or both before complete prosthetic failure is identified and
re-replacement is recommended. In this respect, rates and
risks of reoperation underestimate the impact of valve fail-
ure on mortality.
Even if the conclusions of this study should clearly not be
extrapolated to the older (65 years) patient population, in
which survival after MVR is even more related to patient
comorbidity and not to valve type alone, recommendations854 The Journal of Thoracic and Cardiovascular Surgfor the younger age group of patients (<65 years) should not
be biased by fashionable slogans (bioprostheses for all
patients) or still unproven concepts yet (valve-in-valve
therapy). The evidence to recommend a bioprosthetic valve
for MVR for most younger (<65 years) patients without
relevant comorbidity is still not here. Lifestyle consider-
ations may be important too, but they should never be
placed above the scientific evidence.References
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